Home › Companies › NEKTAR THERAPEUTICS › 2023-2024
Compiled from SEC Form N-PX filings and NEKTAR THERAPEUTICS’s Form 8-K, filed 2024-06-06 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024 2025-2026
Explore NEKTAR THERAPEUTICS in the interactive database Compare manager voting policies
These tallies are NEKTAR THERAPEUTICS’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-06 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Jeff Ajer | 89,572,592 | 5,310,752 | 5,112,487 | -- | 46,683,689 | Majority: yes |
| Elect Director: Robert B. Chess | 87,385,092 | 7,518,984 | 5,091,755 | -- | 46,683,689 | Majority: yes |
| Elect Director: Roy A. Whitfield | 85,885,290 | 8,993,582 | 5,116,959 | -- | 46,683,689 | Majority: yes |
| Proposal 4 The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes. | 87,037,178 | 6,730,748 | 6,227,905 | -- | 46,683,689 | Majority: yes |
Source: NEKTAR THERAPEUTICS, Form 8-K, filed with the SEC on 2024-06-06 — read the filing on EDGAR.
Each item below shows how the 126 asset managers that disclosed a NEKTAR THERAPEUTICS vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of NEKTAR THERAPEUTICS’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 9 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
NEKTAR THERAPEUTICS’s own tally for this item (“Proposal 4 The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes.”): 87,037,178 for, 6,730,748 against, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 183,624,620 outstanding shares: 47.4% for, 4% against (51.1% of the company cast a for/against vote).
The 124 asset managers below cast 99% of the shares they voted on this item FOR (87,230,195 for, 1,126,881 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 18,400,000 | 0 | 0 | 0 | For |
| Vanguard | 12,048,744 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 6,926,347 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 6,305,736 | 0 | 0 | 0 | For |
| Monaco Asset Management SAM | 0 | 0 | 5,030,874 | 0 | Abstain |
| BlackRock | 5,030,483 | 0 | 0 | 0 | For |
| Citadel | 4,484,623 | 0 | 0 | 0 | For |
| Two Sigma | 3,537,152 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 2,962,225 | 0 | 0 | 0 | For |
| Renaissance | 2,952,710 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 2,819,078 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 2,817,753 | 0 | 0 | 0 | For |
| DE Shaw | 2,328,908 | 0 | 0 | 0 | For |
| Charles Schwab | 2,258,260 | 0 | 0 | 0 | For |
| SAMLYN CAPITAL, LLC | 2,073,585 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,053,085 | 0 | 0 | 0 | For |
| Fidelity | 1,996,728 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,233,051 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 1,099,131 | 0 | 0 | Against |
| Invesco | 1,050,250 | 0 | 0 | 0 | For |
| UBS | 948,930 | 0 | 0 | 0 | For |
| State Street | 690,226 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 575,867 | 0 | 0 | 0 | For |
| Dimensional | 459,788 | 0 | 0 | 0 | For |
| Northern Trust | 333,437 | 0 | 0 | 0 | For |
Showing the 25 largest of 124 asset managers. See all 124 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.0% fund support · no official result
The 21 asset managers below cast 99.0% of the shares they voted on this item FOR (23,712,753 for, 220,419 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,980,194 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 6,305,736 | 0 | 0 | 0 | For |
| Fidelity | 1,872,388 | 0 | 0 | 0 | For |
| Charles Schwab | 1,129,130 | 0 | 0 | 0 | For |
| BlackRock | 982,904 | 0 | 0 | 0 | For |
| Invesco | 525,125 | 0 | 0 | 0 | For |
| Nationwide | 277,405 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 256,385 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 219,719 | 0 | 0 | Against |
| GuideStone | 87,519 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,456 | 0 | 0 | 0 | For |
| Dimensional | 50,263 | 0 | 0 | 0 | For |
| Jackson National | 39,748 | 0 | 0 | 0 | For |
| Russell Investments | 32,901 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 29,000 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 28,298 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 24,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 15,605 | 0 | 0 | 0 | For |
| Allianz | 14,311 | 0 | 0 | 0 | For |
| John Hancock | 10,585 | 0 | 0 | 0 | For |
| MIDDLETON & CO INC/MA | 0 | 700 | 0 | 0 | Against |
Combines 2 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: Jeff Ajer”): 89,572,592 for, 5,310,752 against, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 183,624,620 outstanding shares: 48.8% for, 3% against (51.7% of the company cast a for/against vote).
The 20 asset managers below cast 99.0% of the shares they voted on this item FOR (23,712,753 for, 219,719 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,980,194 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 6,305,736 | 0 | 0 | 0 | For |
| Fidelity | 1,872,388 | 0 | 0 | 0 | For |
| Charles Schwab | 1,129,130 | 0 | 0 | 0 | For |
| BlackRock | 982,904 | 0 | 0 | 0 | For |
| Invesco | 525,125 | 0 | 0 | 0 | For |
| Nationwide | 277,405 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 256,385 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 219,719 | 0 | 0 | Against |
| GuideStone | 87,519 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,456 | 0 | 0 | 0 | For |
| Dimensional | 50,263 | 0 | 0 | 0 | For |
| Jackson National | 39,748 | 0 | 0 | 0 | For |
| Russell Investments | 32,901 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 29,000 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 28,298 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 24,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 15,605 | 0 | 0 | 0 | For |
| Allianz | 14,311 | 0 | 0 | 0 | For |
| John Hancock | 10,585 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: Robert B. Chess”): 87,385,092 for, 7,518,984 against, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 183,624,620 outstanding shares: 47.6% for, 4% against (51.7% of the company cast a for/against vote).
The 20 asset managers below cast 99% of the shares they voted on this item FOR (23,582,241 for, 350,231 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,980,194 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 6,305,736 | 0 | 0 | 0 | For |
| Fidelity | 1,872,388 | 0 | 0 | 0 | For |
| Charles Schwab | 1,129,130 | 0 | 0 | 0 | For |
| BlackRock | 982,904 | 0 | 0 | 0 | For |
| Invesco | 525,125 | 0 | 0 | 0 | For |
| Nationwide | 277,405 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 256,385 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 219,719 | 0 | 0 | Against |
| GuideStone | 87,519 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,456 | 0 | 0 | 0 | For |
| Dimensional | 0 | 50,263 | 0 | 0 | Against |
| Jackson National | 0 | 39,748 | 0 | 0 | Against |
| Russell Investments | 32,901 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 29,000 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 28,298 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 24,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 15,605 | 0 | 0 | Against |
| Allianz | 0 | 14,311 | 0 | 0 | Against |
| John Hancock | 0 | 10,585 | 0 | 0 | Against |
Combines 2 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: Roy A. Whitfield”): 85,885,290 for, 8,993,582 against, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 183,624,620 outstanding shares: 46.8% for, 5% against (51.7% of the company cast a for/against vote).
The 20 asset managers below cast 96% of the shares they voted on this item FOR (22,931,243 for, 1,001,229 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,980,194 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 6,305,736 | 0 | 0 | 0 | For |
| Fidelity | 1,872,388 | 0 | 0 | 0 | For |
| Charles Schwab | 1,129,130 | 0 | 0 | 0 | For |
| BlackRock | 982,904 | 0 | 0 | 0 | For |
| Invesco | 0 | 525,125 | 0 | 0 | Against |
| Nationwide | 277,405 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 256,385 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 219,719 | 0 | 0 | Against |
| GuideStone | 87,519 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,456 | 0 | 0 | 0 | For |
| Dimensional | 50,263 | 0 | 0 | 0 | For |
| Jackson National | 39,748 | 0 | 0 | 0 | For |
| Russell Investments | 32,901 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 29,000 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 28,298 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 24,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 15,605 | 0 | 0 | 0 | For |
| Allianz | 14,311 | 0 | 0 | 0 | For |
| John Hancock | 10,585 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
100% fund support · no official result
The 20 asset managers below cast 100% of the shares they voted on this item FOR (23,932,472 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,980,194 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 6,305,736 | 0 | 0 | 0 | For |
| Fidelity | 1,872,388 | 0 | 0 | 0 | For |
| Charles Schwab | 1,129,130 | 0 | 0 | 0 | For |
| BlackRock | 982,904 | 0 | 0 | 0 | For |
| Invesco | 525,125 | 0 | 0 | 0 | For |
| Nationwide | 277,405 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 256,385 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 219,719 | 0 | 0 | 0 | For |
| GuideStone | 87,519 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,456 | 0 | 0 | 0 | For |
| Dimensional | 50,263 | 0 | 0 | 0 | For |
| Jackson National | 39,748 | 0 | 0 | 0 | For |
| Russell Investments | 32,901 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 29,000 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 28,298 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 24,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 15,605 | 0 | 0 | 0 | For |
| Allianz | 14,311 | 0 | 0 | 0 | For |
| John Hancock | 10,585 | 0 | 0 | 0 | For |
Ranked by the number of NEKTAR THERAPEUTICS shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 183,624,620 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Deep Track Capital, LP | 10.02% |
| 2 | Vanguard | 6.56% |
| 3 | PRIMECAP MANAGEMENT CO/CA/ | 3.77% |
| 4 | PRIMECAP Odyssey Funds | 3.43% |
| 5 | Monaco Asset Management SAM | 2.74% |
| 6 | BlackRock | 2.74% |
| 7 | Citadel | 2.44% |
| 8 | Two Sigma | 1.93% |
| 9 | Ensign Peak Advisors, Inc | 1.61% |
| 10 | Renaissance | 1.61% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| TCG Crossover GP II, LLC | 10.92% | DEF14A |
| Deep Track Capital, LP | 10.02% | DEF14A |
| The Vanguard Group | 6.56% | 13G |
| Renaissance Technologies | 2.52% | 13F |
| Millennium Management | 1.63% | 13F |
| Howard W. Robin | 1.55% | DEF14A |
| D.E. Shaw | 1.39% | 13F |
| Two Sigma | 1.13% | 13F |
| Geode Capital | 1.12% | 13F |
| Jonathan Zalevsky, Ph.D. | 0.70% | DEF14A |
Percentages above are of 183,624,620 shares outstanding, as reported by NEKTAR THERAPEUTICS on its Form 10-Q dated 2024-05-02 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NEKTAR THERAPEUTICS’s 10-Q dated 2024-05-02. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At NEKTAR THERAPEUTICS's shareholder meeting held 2024-06-05, in the 2023-2024 proxy season, 126 asset managers reported how they voted in their SEC Form N-PX filings, covering 394 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve a non-binding advisory resolution regarding our executive compensation (a… — FOR was 93% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: NEKTAR THERAPEUTICS's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-06.
NEKTAR THERAPEUTICS proxy season coverage: 2023-2024 (this page) · 2025-2026.